XVI

2D, 3D and 4D soft tissue imaging

Tumor motion is a significant factor inhibiting targeting accuracy in radiation therapy. The development of X-ray volume imaging (XVI) and its suite of imaging tools was driven by the need to visualize internal structures, within the reference frame of the treatment system, to reduce geometric uncertainties. The ability to image at the time of treatment with the patient in the treatment position reduces issues relating to organ movement and inspires clinical confidence to pursue advanced delivery techniques.

XVI imaging technology

规划和治疗3D需要验证3D。XVI的3D成像能力使临床医生能够充分利用复杂的技术，而无需植入标记可视化软组织结构，目标容积和关键结构的位置。

It allows precise registration of the reconstructed image data with the historical CT planning data as a non-invasive procedure. XVI offers a variety of image guided options to suit the individual needs of the patient and the clinic XVI software offers the flexibility to vary the dosage necessary to acquire a VolumeView image, depending on the level of contrast required.

Clinical collaboration

与Elekta Synergy研究小组密切合作，Elekta与其临床合作伙伴合作成为第一家支持IGRT研究的公司，首先将3D容量成像带入临床使用，并将这些解决方案带入更广泛的市场。

Key advantages offered by VolumeView imaging at the time of treatment include:

• Visualization of soft tissue dimensions and position
• 临界器官和肿瘤的可视化
• 骨骼解剖和3D对准的可视化
• Elimination of surrogate markers
• 减少成像剂量的能力
• 能够覆盖在治疗计划系统中定义的结构
• Large field-of-view
• Simultaneous acquisition and reconstruction